New insider activity at United Therapeutics ( (UTHR) ) has taken place on April 16, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
United Therapeutics’ Chairperson and CEO, Martine Rothblatt, recently sold 75 shares of the company’s stock in a transaction totaling $40,271. This insider sale provides investors with a glimpse into executive-level trading activity at the biopharmaceutical firm, as market watchers often track such moves for potential signals about management’s outlook or personal portfolio adjustments.
Recent Updates on UTHR stock
United Therapeutics shares saw renewed analyst interest over the last day as multiple firms updated models ahead of upcoming Q1 biotech earnings, citing sectorwide IQVIA data trends and broader M&A and drug-pricing clarity that support sentiment despite seasonal reimbursement and volume headwinds. Analysts also highlighted stronger confidence in United’s growth drivers, notably potential multi‑billion‑dollar peak sales for Tyvaso in idiopathic pulmonary fibrosis and regulatory momentum such as FDA RMAT designation for miroliverELAP, reinforcing views that key franchises are more likely to stabilize and expand than erode.
Spark’s Take on UTHR Stock
According to Spark, TipRanks’ AI Analyst, UTHR is a Outperform.
Score is driven primarily by standout financial quality (strong growth, very high margins, and a debt-free balance sheet) and supported by positive earnings-call outlook plus multiple favorable clinical and capital-allocation catalysts. Technicals are constructive but not strongly overbought, while valuation is reasonable rather than deeply discounted and lacks dividend yield support.
To see Spark’s full report on UTHR stock, click here.
More about United Therapeutics
YTD Price Performance: 18.54%
Average Trading Volume: 509,153
Technical Sentiment Signal: Buy
Current Market Cap: $25.31B